ADAP Stock Price History and Quote Analysis: Insights for Investors

NASDAQ:ADAP

Adaptimmune Therapeutics plc

$1.08

-0.03-2.70%

At Close 4:00 PM

$1.10

0.02+1.85%

After-Market 05:47 PM

64.51

BESG ScoreESG Rating

profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

Stock Price Today

Adaptimmune Therapeutics plc (ADAP) stock declined over -2.70%, trading at $1.08 on NASDAQ, down from the previous close of $1.11. The stock opened at $1.09, fluctuating between $1.06 and $1.11 in the recent session.

Stock Snapshot

1.11

Prev. Close

1.09

Open

276.16M

Market Cap

255.7M

Number of Shares

1.06

Day Low

1.1098

Day High

-3

P/E Ratio

88.5%

Free Float in %

-0.36

EPS (TTM)

0.17

Book Value

-0.64

Cash Flow per Share

793.63K

Volume

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 10, 2024	1.09	1.11	1.06	1.09	793.63K
Sep 09, 2024	1.08	1.16	1.08	1.11	652.29K
Sep 06, 2024	1.10	1.15	1.08	1.09	1M
Sep 05, 2024	1.17	1.19	1.09	1.11	1.52M
Sep 04, 2024	1.21	1.22	1.14	1.16	787.16K
Sep 03, 2024	1.24	1.32	1.20	1.22	1.24M
Aug 30, 2024	1.26	1.28	1.21	1.27	985.97K
Aug 29, 2024	1.24	1.31	1.21	1.27	1.12M
Aug 28, 2024	1.25	1.25	1.17	1.22	1.26M
Aug 27, 2024	1.30	1.33	1.22	1.24	1.21M
Aug 26, 2024	1.23	1.33	1.20	1.33	1.67M
Aug 23, 2024	1.16	1.23	1.16	1.21	1.06M
Aug 22, 2024	1.19	1.26	1.17	1.17	1.35M
Aug 21, 2024	1.08	1.19	1.08	1.19	1.9M
Aug 20, 2024	1.11	1.13	1.02	1.05	2.03M
Aug 19, 2024	1.08	1.12	1.05	1.12	1.63M
Aug 16, 2024	1.09	1.09	1.04	1.08	999.8K
Aug 15, 2024	1.08	1.09	1.05	1.09	915.46K
Aug 14, 2024	1.06	1.08	1.00	1.04	1.44M
Aug 13, 2024	1.11	1.15	1.04	1.05	1.97M

Contact Details

Abingdon, OX14 4RX

United Kingdom

Website: https://www.adaptimmune.comContact: 441 235 430000

About Company

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Frequently Asked Questions

What is the current Adaptimmune Therapeutics plc (ADAP) stock price?

Adaptimmune Therapeutics plc (NASDAQ: ADAP) stock price is $1.08 in the last trading session. During the trading session, ADAP stock reached the peak price of $1.11 while $1.06 was the lowest point it dropped to. The percentage change in ADAP stock occurred in the recent session was -2.7% while the dollar amount for the price change in ADAP stock was -$0.03.

ADAP's industry and sector of operation?

The NASDAQ listed ADAP is part of Biotechnology industry that operates in the broader Healthcare sector. Adaptimmune Therapeutics plc designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ADAP?

Dr. Rafael G. Amado M.D.
Pres and Head of Global Oncology R&D
Mr. Adrian G. Rawcliffe
Chief Executive Officer, Principal Accounting Officer & Director
Dr. Juli P. Miller Ph.D.
Vice President of Investor Relations
Ms. Kerry Sharp
Senior Vice President & Gen. Council
Ms. Margaret Henry
Head of PR & Company Sec.
Mr. William C. Bertrand Jr., Esq., J.D.
Chief Operating Officer
Mr. John Lunger
Chief Patient Supply Officer
Dr. Elliot Norry B.A., M.D.
Chief Medical Officer
Dr. Helen Katrina Tayton-Martin MBA, Ph.D.
Co-Founder & Chief Bus. & Strategy Officer
Mr. Gavin Hilary James Wood BA (Hons), ACA
Chief Financial Officer
Ms. Joanna Brewer Ph.D.
Chief Scientific Officer

How ADAP did perform over past 52-week?

ADAP's closing price is 157.14% higher than its 52-week low of $0.42 where as its distance from 52-week high of $2.05 is -47.32%.

How many employees does ADAP have?

Number of ADAP employees currently stands at 449.

Link for ADAP official website?

Official Website of ADAP is: https://www.adaptimmune.com

How do I contact ADAP?

ADAP could be contacted at phone 441 235 430000 and can also be accessed through its website. ADAP operates from 60 Jubilee Avenue, Abingdon, OX14 4RX, United Kingdom.

How many shares of ADAP are traded daily?

ADAP stock volume for the day was 793.63K shares. The average number of ADAP shares traded daily for last 3 months was 1.88M.

What is the market cap of ADAP currently?

The market value of ADAP currently stands at $276.16M with its latest stock price at $1.08 and 255.7M of its shares outstanding.

Employees	449
Beta	2.203
Sales or Revenue	$60.51M
5Y Sales Change%	-0.507%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology